Avacta Group plc is a UK-based biotechnology company specializing in the discovery, development and commercialization of Affimer® biotherapeutics and diagnostic reagents. The company’s proprietary Affimer platform uses small, engineered protein scaffolds that can be tailored to bind specifically to target molecules, offering an alternative to traditional antibodies. Avacta operates two core divisions: Avacta Therapeutics, which focuses on novel treatments in oncology and immune-related diseases, and Avacta Analytical, which develops reagents and point-of-care diagnostic tests.
In its diagnostics business, Avacta has applied the Affimer technology to lateral flow assays, most notably for rapid detection of viral pathogens such as SARS-CoV-2. These tests are designed for high sensitivity and specificity in clinical and non-clinical settings. Avacta Analytical also supplies research-use-only Affimer reagents to academic institutions and life sciences companies, supporting applications in proteomics, drug discovery and biomarker detection.
Avacta was founded in 2005 and is headquartered in Wetherby, West Yorkshire, with R&D and manufacturing facilities in the UK. The company has raised capital through listings on the London Stock Exchange’s AIM market and maintains a secondary trading presence on the OTC Markets in the United States. Over the years, Avacta has entered into collaboration agreements with global pharmaceutical and diagnostic partners to advance its pipeline and broaden market reach.
Led by CEO and co-founder Dr. Alastair Smith, Avacta’s management team combines scientific expertise with commercial and regulatory experience. The company continues to expand its pipeline of Affimer-based therapeutics in oncology and immunology, while further developing point-of-care diagnostic solutions for infectious diseases and other medical applications.
AI Generated. May Contain Errors.
